<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN" "http://jats.nlm.nih.gov/publishing/1.2/JATS-journalpublishing1.dtd">
<article article-type="research-article" dtd-version="1.2" xml:lang="ru" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="issn">2687-0940</journal-id><journal-title-group><journal-title>Актуальные проблемы медицины</journal-title></journal-title-group><issn pub-type="epub">2687-0940</issn></journal-meta><article-meta><article-id pub-id-type="doi">10.52575/2687-0940-2023-46-1-5-15</article-id><article-id pub-id-type="publisher-id">139</article-id><article-categories><subj-group subj-group-type="heading"><subject>ВНУТРЕННИЕ БОЛЕЗНИ</subject></subj-group></article-categories><title-group><article-title>&lt;strong&gt;Метаболические нарушения в постковидном периоде&lt;/strong&gt;</article-title><trans-title-group xml:lang="en"><trans-title>&lt;strong&gt;Metabolic Disorders the Post-COVID Period&lt;/strong&gt;</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Панина</surname><given-names>Юлия Николаевна</given-names></name><name xml:lang="en"><surname>Panina</surname><given-names>Yulia N.</given-names></name></name-alternatives><email>doc.panina@yandex.ru</email></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Вишневский</surname><given-names>Валерий Иванович</given-names></name><name xml:lang="en"><surname>Vishnevskij</surname><given-names>Valery I.</given-names></name></name-alternatives><email>vishnevsky.orel@mail.ru</email></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Мельчинская</surname><given-names>Евгения Николаевна</given-names></name><name xml:lang="en"><surname>Melchinskaja</surname><given-names>Evgenia N.</given-names></name></name-alternatives></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Вишневский</surname><given-names>Матвей Вадимович</given-names></name><name xml:lang="en"><surname>Vishnevskij</surname><given-names>Matvei V.</given-names></name></name-alternatives></contrib></contrib-group><pub-date pub-type="epub"><year>2023</year></pub-date><volume>46</volume><issue>1</issue><fpage>0</fpage><lpage>0</lpage><self-uri content-type="pdf" xlink:href="/media/journal-medicine/2023/1/АПМ_2023_5-15_Ch7BqmL.pdf" /><abstract xml:lang="ru"><p>Около пятой части населения мира страдает одним или несколькими хроническими заболеваниями, что подвергает их повышенному риску тяжелого течения коронавирусной инфекции COVID-19. При этом нередко выявляют метаболические расстройства, наличие которых играет важную роль в патогенезе COVID-19 и сопутствует более тяжёлым проявлениям заболевания. Наибольшее количество госпитализаций и смертей в мире, связанных с новой коронавирусной инфекцией, приходится на людей пожилого и старческого возраста. Возраст и сопутствующие заболевания, характерные для пожилых людей, такие как ожирение, сахарный диабет, артериальная гипертония, легочная, сердечно-сосудистая, почечная недостаточность, влияют на прогрессирование и прогноз COVID-19. Теперь, спустя более чем через 2 года после первоначальной вспышки SARS-CoV-2, имеются убедительные доказательства того, что люди с метаболическими заболеваниями не только более восприимчивы к тяжелому COVID-19, но и имеют повышенный риск определенных осложнений. Таким образом, первичная профилактика остается лучшей стратегией, позволяющей избежать постковидный синдром и связанных с ним метаболических нарушений.</p></abstract><trans-abstract xml:lang="en"><p>About a fifth of the world&amp;#39;s population suffers from one or more chronic diseases, which exposes them to an increased risk of severe coronavirus infection COVID-19. At the same time, metabolic disorders are often detected, the presence of which plays an important role in the pathogenesis of COVID-19 and is accompanied by a more severe manifestation of the disease. The largest number of hospitalizations and deaths in the world associated with a new coronavirus infection falls on elderly and senile people. Age and concomitant diseases characteristic of the elderly, such as obesity, diabetes mellitus, arterial hypertension, pulmonary, cardiovascular, and renal insufficiency affect the progression and prognosis of COVID-19. Now, more than 2 years after the initial outbreak of SARS-CoV-2, there is strong evidence that people with metabolic diseases are not only more susceptible to severe COVID-19, but also have an increased risk of certain complications. Thus, primary prevention remains the best strategy to avoid post-COVID syndrome and associated metabolic disorders.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>COVID-19</kwd><kwd>постковидный синдром</kwd><kwd>long COVID</kwd><kwd>метаболические нарушения</kwd><kwd>гипергликемия</kwd></kwd-group><kwd-group xml:lang="en"><kwd>COVID-19</kwd><kwd>postCOVID syndrome</kwd><kwd>long COVID</kwd><kwd>metabolic disorders</kwd><kwd>hyperglycemia</kwd></kwd-group></article-meta></front><back><ref-list><title>Список литературы</title><ref id="B1"><mixed-citation>Белoцеркoвcкaя Ю.Г., Рoмaнoвcких A.Г., Cмирнoв И.П., Cинoпaльникoв A.И. 2021. Дoлгий COVID-19. Consilium Medicum. 23 (3): 261&amp;ndash;268. doi: 10.26442/20751753.2021.3.200805</mixed-citation></ref><ref id="B2"><mixed-citation>Бoндaрев C.A., Aчкacoв Е.Е., Cмирнoв В.В., Шишкин A.Н., Худякoвa Н.В., Рыбкa Т.Г. 2020. Влияние артериальной гипертензии и других факторов риска на развитие фибрилляции предсердий у спортсменов. Артериальная гипертензия. 26 (4): 362&amp;ndash;370. doi: 10.18705/1607-419X-2020-26-4-362-370</mixed-citation></ref><ref id="B3"><mixed-citation>Кoгaн Е.A., Березoвcкий Ю.C., Прoценкo Д.Д., Бaгдacaрян Т.Р., Грецoв Е.М., Демурa C.A., Демяшкин Г.A., Кaлинин Д.В., Куклевa A.Д., Курилинa Э.В., Некрacoвa Т.П., Пaрaмoнoвa&amp;nbsp;Н.Б., Пoнoмaрев A.Б., Рaденcкa-Лoпoвoк C.Г., Cеменoвa Л.A., Тертычный A.C. 2020. Патологическая анатомия инфекции, вызванной SARS-CoV-2. Судебная медицина. 6&amp;nbsp;(2): 8&amp;ndash;30. doi: 10.19048/2411-8729-2020-6-2-8-30</mixed-citation></ref><ref id="B4"><mixed-citation>Oйнoткинoвa O.Ш., Мacленникoвa O.М., Лaринa В.Н., Ржевcкaя Е.В., Cырoв A.В., Дедoв Е.И., Крюкoв Е.В., Еcин Е.В., Журaвлевa М.В., Вoевoдa М.И., Демидoвa Т.Ю., Aчкacoв Е.Е., Cпaccкий A.A., Шaхнoвич П.Г. 2020. Coглacoвaннaя экcпертнaя пoзиция пo диaгнocтике и лечению фульминaнтнoгo миoкaрдитa в уcлoвиях пaндемии COVID-19. Aкaдемия медицины и cпoртa. 1 (2): 28&amp;ndash;40. doi: 10.15829/2712-7567-2020-2-13</mixed-citation></ref><ref id="B5"><mixed-citation>Oрлoв Ю.П., Гoвoрoвa Н.В., Кoрпaчевa O.В., Aфaнacьев В.В., Хиленкo И.A. 2021. O вoзмoжнocти иcпoльзoвaния препaрaтoв группы cукцинaтoв в уcлoвиях гипoкcии при COVID-19. Oбщaя реaнимaтoлoгия. 17 (3): 78&amp;ndash;98. doi: 10.15360/1813-9779-2021-3-78-98</mixed-citation></ref><ref id="B6"><mixed-citation>Уcaчевa Е.В. 2016. Мифы и реaльнocть кaрдиoпрoтективнoй терaпии. 24 (9): 546&amp;ndash;550.</mixed-citation></ref><ref id="B7"><mixed-citation>Acuti Martellucci C., Flacco M.E., Cappadona R., Bravi F., Mantovani L., Manzoli L. 2020. SARS-CoV-2 pandemic: An. overview. Adv. Biol. Regul. 77: 100736. doi: 10.1016/j.jbior.2020.100736</mixed-citation></ref><ref id="B8"><mixed-citation>Adhikari S.P., Meng S., Wu Y.J., Mao Y.P., Ye R.X., Wang Q.Z., Sun C., Sylvia S., Rozelle S., Raat H., Zhou H. 2020. Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review. Infect. Dis. Poverty. 9 (1): 29. doi: 10.1186/s40249-020-00646-x</mixed-citation></ref><ref id="B9"><mixed-citation>Alfano G., Fontana F., Mori G., Giaroni F., Ferrari A., Giovanella S., Ligabue G., Ascione E., Cazzato S., Ballestri M., Di Gaetano M., Meschiari M., Menozzi M., Milic J., Andrea B., Franceschini E., Cuomo G., Magistroni R., Mussini C., Cappelli G., Guaraldi G. 2022. Modena COVID-19 Working Group (MoCo19). Acid base disorders in patients with COVID-19. Int. Urol. Nephrol. 54 (2): 405&amp;ndash;410. doi: 10.1007/s11255-021-02855-1</mixed-citation></ref><ref id="B10"><mixed-citation>Avanzato V.A., Matson M.J., Seifert S.N., Pryce R., Williamson B.N., Anzick S.L., Barbian K., Judson&amp;nbsp;S.D., Fischer E.R., Martens C., Bowden T.A., de Wit E., Riedo F.X., Munster V.J. 2020. Case study: Prolonged infectious SARSCoV-2 shedding from an asymptomatic immunocompromised cancer patient. Cell. 183 (7): 1901&amp;ndash;1912. doi: 10.1016/j.cell.2020.10.049</mixed-citation></ref><ref id="B11"><mixed-citation>Bezuidenhout M.C., Wiese O.J., Moodley D., Maasdorp E., Davids M.R., Koegelenberg C.F., Lalla U., Khine-Wamono A.A., Zemlin A.E., Allwood B.W. 2021. Correlating arterial blood gas, acid-base and blood pressure abnormalities with outcomes in COVID-19 intensive care patients. Ann. Clin. Biochem. 58 (2): 95&amp;ndash;101. doi: 10.1177/0004563220972539</mixed-citation></ref><ref id="B12"><mixed-citation>Cariou B., Pichelin M., Goronflot T., Gonfroy C., Marre M., Raffaitin-Cardin C., Thivolet C., Wargny&amp;nbsp;M., Hadjadj S., Gourdy P. 2021. CORONADO investigators. Phenotypic characteristics and prognosis of newly diagnosed diabetes in hospitalized patients with COVID-19: results from the CORONADO study. Diabetes Res. Clin. Pract.175. doi: 10.1016/j.diabres.2021.108695</mixed-citation></ref><ref id="B13"><mixed-citation>Carrasco-S&amp;aacute;nchez F.J., L&amp;oacute;pez-Carmona M.D., Mart&amp;iacute;nez-Marcos F.J., P&amp;eacute;rez-Belmonte L.M., Hidalgo-Jim&amp;eacute;nez A., Buonaiuto V., Su&amp;aacute;rez Fern&amp;aacute;ndez C., Freire Castro S.J., Luordo D., Pesqueira Fontan&amp;nbsp;P.M., Bl&amp;aacute;zquez Encinar J.C., Magallanes Gamboa J.O., de la Pe&amp;ntilde;a Fern&amp;aacute;ndez A., Torres&amp;nbsp;Pe&amp;ntilde;a J.D., Fern&amp;aacute;ndez Sol&amp;agrave; J., Napal Lecumberri J.J., Amor&amp;oacute;s Mart&amp;iacute;nez F., Guisado Espartero M.E., Jorge Ripper C., G&amp;oacute;mez M&amp;eacute;ndez R., Vicente L&amp;oacute;pez N., Rom&amp;aacute;n Bernal B., Rojano Rivero M.G., Ramos Rinc&amp;oacute;n J.M., G&amp;oacute;mez Huelgas R. 2021. SEMI-COVID-19 Network. Admission hyperglycaemia as a predictor of mortality in patients hospitalized with COVID-19 regardless of diabetes status: data from the Spanish SEMI-COVID-19 Registry. Ann. Med. 53 (1): 103&amp;ndash;116. doi: 10.1080/07853890.2020.1836566</mixed-citation></ref><ref id="B14"><mixed-citation>Casta&amp;ntilde;eda S., Remuzgo-Mart&amp;iacute;nez S., L&amp;oacute;pez-Mej&amp;iacute;as R., Genre F., Calvo-Al&amp;eacute;n J., Llorente I., Aurrecoechea E., Ortiz A.M., Triguero A., Blanco R., Llorca J., Gonz&amp;aacute;lez-Gay M.A. 2019. Rapid beneficial effect of the IL-6 receptor blockade on insulin resistance and insulin sensitivity in non-diabetic patients with rheumatoid arthritis. Clin Exp Rheumatol. 37: 465&amp;ndash;473.</mixed-citation></ref><ref id="B15"><mixed-citation>De Leo S., Lee S.Y., Braverman L.E. Hyperthyroidism. Lancet 2016; 388: 906&amp;ndash;918. doi: 10.1016/S0140-6736(16)00278-6</mixed-citation></ref><ref id="B16"><mixed-citation>Group R.C. 2021. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 397: 1637&amp;ndash;1645. doi: 10.1016/S0140-6736(21)00676-0</mixed-citation></ref><ref id="B17"><mixed-citation>Guerstein S., Romeo-Aznar V., Dekel M., Miron O., Davidovitch N., Puzis R., Pilosof S. 2021. The interplay between vaccination and social distancing strategies affects COVID19 population-level outcomes. PLoS Comput Biol. 17 (8): e1009319. doi: 10.1371/journal.pcbi.1009319</mixed-citation></ref><ref id="B18"><mixed-citation>Inaba H., Aizawa T. 2021. Coronavirus Disease 2019 and the Thyroid &amp;ndash; Progress and Perspectives. Front Endocrinol (Lausanne). 12: 708333. doi: 10.3389/fendo.2021.708333</mixed-citation></ref><ref id="B19"><mixed-citation>Kosiborod M.N., Esterline R., Furtado R.H.M., Oscarsson J., Gasparyan S.B., Koch G.G., Martinez F., Mukhtar O., Verma S., Chopra V., Buenconsejo J., Langkilde A.M., Ambery P., Tang F., Gosch&amp;nbsp;K., Windsor S.L., Akin E.E., Soares R.V.P., Moia D.D.F., Aboudara M., Hoffmann Filho&amp;nbsp;C.R., Feitosa A.D.M., Fonseca A., Garla V., Gordon R.A., Javaheri A., Jaeger C.P., Leaes&amp;nbsp;P.E., Nassif M., Pursley M., Silveira F.S., Barroso W.K.S., Lazcano Soto J.R., Nigro Maia&amp;nbsp;L., Berwanger O. 2021. Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 9: 586&amp;ndash;594. doi: 10.1016/S2213-8587(21)00180-7</mixed-citation></ref><ref id="B20"><mixed-citation>Kudose S., Batal I., Santoriello D., Xu K., Barasch J., Peleg Y., Canetta P., Ratner L.E., Marasa M., Gharavi A.G., Stokes M.B., Markowitz G.S, D&amp;#39;Agati V.D. 2020. Kidney biopsy findings in patients with COVID-19. Journal of the American Society of Nephrology. 9 (31): 1959&amp;ndash;1968. doi: 10.1681/ASN.2020060802</mixed-citation></ref><ref id="B21"><mixed-citation>Mallah S.I., Ghorab O.K., Al-Salm S., Abdellatif O.S., Tharmaratnam T., Iskandar M A., Sefen, J.A.N., Sidhu P., Atallah B., El-Lababid, R., Al-Qahtan M. 2021. COVID-19: breaking down a global health crisis. Ann Clin Microbiol Antimicrob. 201: 35. doi: 10.1186/s12941-021-00438-7</mixed-citation></ref><ref id="B22"><mixed-citation>Marfella R., Paolisso P., Sardu C., Bergamaschi L., D&amp;#39;Angelo E.C., Barbieri M., Rizzo M.R., Messina V., Maggi P., Coppola N., Pizzi C., Biffi M., Viale P., Gali&amp;eacute; N., Paolisso G. 2020. Negative impact of hyperglycaemia on tocilizumab therapy in COVID-19 patients. Diabetes Metab. 46: 403&amp;ndash;405. doi: 10.1016/j.diabet.2020.05.005</mixed-citation></ref><ref id="B23"><mixed-citation>Mazori A.Y., Bass I.R., Chan L., Mathews K.S., Altman D.R., Saha A., Soh H., Wen H.H., Bose S., Leven E., Wang J.G., Mosoyan G., Pattharanitima P., Greco G., Gallagher E.J. 2021. Hyperglycemia is associated with increased mortality in critically ill patients with COVID-19. Endocr Pract. 27 (2): 95&amp;ndash;100. doi: 10.1016/j.eprac.2020.12.015</mixed-citation></ref><ref id="B24"><mixed-citation>Michelen M., Manoharan L., Elkheir N., Cheng V., Dagens A., Hastie C., O&amp;#39;Hara M., Suett J., Dahmash&amp;nbsp;D., Bugaeva P., Rigby I., Munblit D., Harriss E., Burls A., Foote C., Scott J., Carson G., Olliaro P., Sigfrid L., Stavropoulou C. 2021. Characterising long COVID: a living systematic review. BMJ Global Health. 6: e005427. doi: 10.1136/bmjgh-2021-005427</mixed-citation></ref><ref id="B25"><mixed-citation>National Center for Biotechnology Information. 2022. PubChem Compound Summary for CID 10917, Levocarnitine. 2022; from https://pubchem.ncbi.nlm.nih.gov/compound/Levocarnitine.</mixed-citation></ref><ref id="B26"><mixed-citation>Noh Y., Oh I.S., Jeong H.E., Filion K.B., Yu O.H.Y., Shin J.Y. 2021. Association between DPP-4 inhibitors and COVID-19-related outcomes among patients with type 2 diabetes. Diabetes Care. 44: e64&amp;ndash;e66. doi: 10.2337/dc20-1824</mixed-citation></ref><ref id="B27"><mixed-citation>Post-COVID Conditions. CDC, 2021, Updated July 12. 2021. [https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html].</mixed-citation></ref><ref id="B28"><mixed-citation>Raman B., Bluemke D.A., L&amp;uuml;scher T.F., Neubauer S. 2022. Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus. Eur. Heart J. 43: 1157&amp;ndash;1172. doi: 10.1093/eurheartj/ehac031</mixed-citation></ref><ref id="B29"><mixed-citation>Santos A., Magro D.O, Evangelista-Poderoso R., Saad M.J.A. 2021. Diabetes, obesity, and insulin resistance in COVID-19: molecular interrelationship and therapeutic implications. Diabetol Metab Syndr.13: 23. doi: 10.1186/s13098-021-00639-2</mixed-citation></ref><ref id="B30"><mixed-citation>Scappaticcio L., Pitoia F., Esposito K., Piccardo A., Trimboli P. 2021. Impact of COVID-19 on the thyroid gland: an update. Rev Endocr Metab Disord. 22 (4): 803-815. doi: 10.1007/s11154-020-09615-z</mixed-citation></ref><ref id="B31"><mixed-citation>Seeherman S., Suzuki Y.J. 2021. Viral Infection and Cardiovascular Disease: Implications for the Molecular Basis of COVID-19 Pathogenesis. Int. J. Mol. Sci. 22 (4): 1659. doi: 10.3390/ijms22041659</mixed-citation></ref><ref id="B32"><mixed-citation>Solerte S.B., D&amp;#39;Addio F., Trevisan R., Lovati E., Rossi A., Pastore I., Dell&amp;#39;Acqua M., Ippolito E., Scaranna C., Bellante R., Galliani S., Dodesini A.R., Lepore G., Geni F., Fiorina R.M., Catena E., Corsico A., Colombo R., Mirani M., De Riva C., Oleandri S.E., Abdi R., Bonventre J.V., Rusconi&amp;nbsp;S., Folli F., Di Sabatino A., Zuccotti G., Galli M., Fiorina P. 2020. Sitagliptin treatment at the time of hospitalization was associated with reduced mortality in patients with type 2 diabetes and COVID-19: a multicenter, case-control, retrospective, observational study. Diabetes Care. 43: 2999&amp;ndash;3006. doi: 10.2337/dc20-1521</mixed-citation></ref><ref id="B33"><mixed-citation>Velavan T.P., Kieu Linh L.T., Kreidenweiss A., Gabor J., Krishna S., Kremsner P.G. 2021. Longitudinal monitoring of lactate in hospitalized and ambulatory COVID-19 patients. Am. J. Trop. Med. Hyg. 104 (3): 1041&amp;ndash;1044. doi: 10.4269/ajtmh.20-1282</mixed-citation></ref><ref id="B34"><mixed-citation>Zhou H., Yang J., Zhou C., Chen B., Fang H., Chen S., Zhang X., Wang L., Zhang L. 2021. A Review of SARS-CoV2: compared With SARS-CoV and MERS-CoV. Front Med (Lausanne). 8:628370. doi: 10.3389/fmed.2021.628370</mixed-citation></ref></ref-list></back></article>